Vancomycin "telephone"

Clinical Infectious Diseases

Volumn 53, Issue 2, 2011, Pages 211-212

  Drekonja, Dimitri M ^a,b,c  

^a Minneapolis Veterans Affairs Health Care System   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL PROTOCOL; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; FECES ANALYSIS; FOLLOW UP; HUMAN; LETTER; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; METRONIDAZOLE; TREATMENT OUTCOME; VANCOMYCIN;

EID: 79959742278     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir311     Document Type: Letter

References (4)

1. Studemeister A. Lack of health insurance coverage for oral vancomycin: It's time to tackle the elephant in the room. Clin Infect Dis 2011; 52:691-2.
2. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7. (Pubitemid 47101025)
3. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
4. Pakyz AL, Carroll NV, Harpe SE, Oinonen M, Polk RE. Increase in use of vancomycin for Clostridium difficile infection in US hospitals. Infect Control Hosp Epidemiol 2010; 31:867-8.